Performance evaluation of newly developed fluorescence immunoassay-based interferon-gamma release assay for the diagnosis of latent tuberculosis infection in healthcare workers

Oh Joo Kweon; Yong Kwan Lim; Hye Ryoun Kim; Tae-Hyoung Kim; Mi-Kyung Lee

doi:10.1016/j.jmii.2021.05.007

Performance evaluation of newly developed fluorescence immunoassay-based interferon-gamma release assay for the diagnosis of latent tuberculosis infection in healthcare workers

J Microbiol Immunol Infect. 2022 Apr;55(2):328-331. doi: 10.1016/j.jmii.2021.05.007. Epub 2021 May 29.

Authors

Oh Joo Kweon¹, Yong Kwan Lim¹, Hye Ryoun Kim¹, Tae-Hyoung Kim², Mi-Kyung Lee³

Affiliations

¹ Department of Laboratory Medicine, Chung-Ang University College of Medicine, Seoul, Republic of Korea.
² Department of Urology, Chung-Ang University College of Medicine, Seoul, Republic of Korea.
³ Department of Laboratory Medicine, Chung-Ang University College of Medicine, Seoul, Republic of Korea. Electronic address: [email protected].

PMID: 34127404
DOI: 10.1016/j.jmii.2021.05.007

Abstract

The ichroma™ IGRA-TB (Boditech Med Inc., Chuncheon, Republic of Korea) is an automated fluorescent immunoassay-based point-of-care interferon-gamma release assay for detecting latent tuberculosis infection. We evaluated this assay with 408 health care workers, and demonstrated its acceptable performances comparing to QuantiFERON-TB Gold-Plus (QFT-Plus; Qiagen, Germantown, MD).

Keywords: Interferon-gamma release assay; Latent tuberculosis infection; QuantiFERON-TB Gold-plus; ichroma™ IGRA-TB.

MeSH terms

Health Personnel
Humans
Immunoassay
Interferon-gamma Release Tests*
Latent Tuberculosis* / diagnosis
Tuberculin Test